DePuy Synthes unveils new surgical imaging system that cuts costs

J&J’s DePuy Synthes unveiled its latest surgical imaging offering that’s designed to be more affordable in hopes of opening up access to advanced imaging tech.

Dubbed the KICK System with FluoroExpress Software Module, the package is compatible with the VIPER System and the EXPEDIUM Spine System of implants, and improved visualization during minimally invasive and open procedures to treat a broad range of spinal disorders, the company said. The technology allows real-time intraoperative viewing of instrumentation and implants relative to a patient’s anatomy for proper pedicle screw placement.

The technology is part of a partnership with DePuy and Brainlab.


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

Only about 11% of spinal surgeons in the U.S. and Europe use advanced imaging technology, and DePuy is hoping to grow that number with the new system.

"The KICK System enhances less invasive surgery for the clinician who may not have access to expensive 3D imaging systems, but recognizes the need for advanced imaging to support a successful fusion procedure and help improve patient outcomes," Dan Wildman, platform leader at DePuy, said in a statement. "Through solutions such as the KICK System, we are improving access to care and creating and delivering clinical and economic value to healthcare systems worldwide."

By using a small, portable infrared camera with a computer and monitor, the system easily navigates between operating rooms and works together with existing X-ray equipment to support surgical workflow. The monitor displays up to four different X-ray images at one time to make X-ray equipment's repositioning to capture different views unnecessary, which reduces radiation exposure and surgery time.

Suggested Articles

The FDA granted an expanded indication to GT Medical’s GammaTile cancer therapy, broadening its use to newly diagnosed brain cancer patients.

A new company focusing on sperm rather than egg biology debuted with goals of increasing fertility rates and reducing pregnancy complications.

China’s Biotheus picked up the rights to Tilt Biotherapeutics’ lead oncolytic virus program in greater China.